3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasm Metastasis
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Interventions
Imatinib Mesylate
6
Sunitinib
4
ripretinib
2
regorafenib
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
trastuzumab deruxtecan
1
pemigatinib
1
olverembatinib
1
envafolimab
1
atezolizumab
1
apatinib
1
Temozolomide
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Midazolam
1
Laparoscopy
1
Ipilimumab
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Biopsy
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
nilotinib
×
90 days
×
Clear all
No trials found.